{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:04:59Z","timestamp":1773252299860,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3-4","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma outcomes are influenced by sociodemographic factors, including health insurance. Military beneficiaries, which include servicemembers, veterans, and their families, are often treated in civilian settings with TRICARE or Veterans Affairs acting as an insurance payor. We sought to examine outcomes among military and veteran beneficiaries with localized pancreatic cancer treated in civilian hospitals using the National Cancer Database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Patients age &amp;lt;65 with stage I-III PDAC from 2010 to 2020 with private or other government insurance were included. Stage-stratified overall survival was analyzed using the Kaplan-Meier and multivariate Cox proportional hazards model. Logistic regression models were used to examine receipt of therapy and postoperative mortality. Survival analysis was examined after propensity score matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 21,691 patients meeting inclusion criteria, 781 had other government insurance. Military beneficiaries were more likely than privately insured patients to be male and Black, and to live in low-income and rural areas. They traveled further for care and started treatment later. Furthermore, military beneficiaries were less likely to receive chemotherapy and undergo surgery. After adjusting for clinicopathologic factors, postoperative mortality was higher for military beneficiaries at 30 days (odds ratio 3.51, 95% confidence interval 1.70-7.27) and 90 days (odds ratio 3.36, 95% confidence interval 1.89-5.96). Median overall survival for privately insured patients was 18.5 months versus 14.7 for military (P\u2009&amp;lt;\u2009.001). Military insurance remained independently associated with worse overall survival (hazard ratio 1.15, 95% CI 1.03-1.29; P\u2009=\u2009.015). After propensity score matching, stage-stratified overall survival remained inferior for military beneficiaries (P\u2009=\u2009.004).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with localized pancreatic cancer, military beneficiaries were less likely to receive cancer treatment, had worse postoperative mortality, and experienced worse risk-adjusted overall survival versus individuals with private insurance. Further research is needed to investigate potential disparities in access to care and treatment outcomes among military beneficiaries and to evaluate policies aimed at closing this gap.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/milmed\/usaf465","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:47:38Z","timestamp":1756986458000},"page":"e789-e797","source":"Crossref","is-referenced-by-count":0,"title":["Localized Pancreatic Cancer among Military Beneficiaries: A National Cancer Database Analysis"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5912-0902","authenticated-orcid":false,"given":"R Connor","family":"Chick","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8267-8979","authenticated-orcid":false,"given":"Patrick W","family":"Underwood","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-3123","authenticated-orcid":false,"given":"Robert W","family":"Krell","sequence":"additional","affiliation":[{"name":"Department of Surgery, Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4036-7715","authenticated-orcid":false,"given":"Elizabeth L","family":"Barbera","sequence":"additional","affiliation":[{"name":"Department of Surgery, Brooke Army Medical Center , San Antonio, TX 78240,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Heslin","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Texas Southwestern Medical Center , Dallas, TX 75390,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3113-6560","authenticated-orcid":false,"given":"Alex C","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Texas Southwestern Medical Center , Dallas, TX 75390,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-8433","authenticated-orcid":false,"given":"Jordan M","family":"Cloyd","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-4340","authenticated-orcid":false,"given":"Joal D","family":"Beane","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"2026031018444651200_usaf465-B1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026031018444651200_usaf465-B2","first-page":"e35857","article-title":"Socioeconomic factors associated with a late-stage pancreatic cancer diagnosis: an analysis of the national cancer database","volume":"15","author":"Gallegos","year":"2023","journal-title":"Cureus"},{"key":"2026031018444651200_usaf465-B3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.amjsurg.2018.12.007","article-title":"Healthcare disparities in outcomes of patients with resectable pancreatic cancer","volume":"217","author":"Moaven","year":"2019","journal-title":"Am J Surg"},{"key":"2026031018444651200_usaf465-B4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/jso.27697","article-title":"Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: a national and local perspective","volume":"130","author":"Fromer","year":"2024","journal-title":"J Surg Oncol"},{"key":"2026031018444651200_usaf465-B5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026031018444651200_usaf465-B6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/jso.27275","article-title":"Identifying patient profiles of disparate care in resectable pancreas cancer using latent class analysis","volume":"128","author":"Maduekwe","year":"2023","journal-title":"J Surg Oncol"},{"key":"2026031018444651200_usaf465-B7","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1245\/s10434-023-13230-y","article-title":"Disparities in NCCN guideline-compliant care for patients with early-stage pancreatic adenocarcinoma at minority-serving versus non-minority-serving hospitals","volume":"30","author":"Lima","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026031018444651200_usaf465-B8","first-page":"13","article-title":"Current and projected characteristics and unique health care needs of the patient population served by the Department of Veterans Affairs","volume":"5","author":"Eibner","year":"2016","journal-title":"Rand Health Q"},{"key":"2026031018444651200_usaf465-B9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/heq.2022.0128","article-title":"Nondisparate survival of non-hispanic black women with breast cancer despite less favorable pathology: effect of access to and provision of care within a military health care system","volume":"7","author":"Darmon","year":"2023","journal-title":"Health Equity"},{"key":"2026031018444651200_usaf465-B10","doi-asserted-by":"crossref","first-page":"102520","DOI":"10.1016\/j.canep.2023.102520","article-title":"Treatment of pancreatic adenocarcinoma in relation to survival in the U.S. Military Health System","volume":"88","author":"Eaglehouse","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"2026031018444651200_usaf465-B11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1188\/20.CJON.331-334","article-title":"Veterans with cancer: providing care in the community","volume":"24","author":"Laudon Thomas","year":"2020","journal-title":"Clin J Oncol Nurs"},{"key":"2026031018444651200_usaf465-B12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1475-6773.13885","article-title":"In defense of direct care: limiting access to military hospitals could worsen quality and safety","volume":"57","author":"Zogg","year":"2022","journal-title":"Health Serv Res"},{"key":"2026031018444651200_usaf465-B13","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","article-title":"Incident cases captured in the National Cancer Database compared with Those in U.S. population based central cancer registries in 2012-2014","volume":"26","author":"Mallin","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2026031018444651200_usaf465-B14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.hpb.2023.11.008","article-title":"Understanding surgical attrition for \u201cresectable\u201d pancreatic cancer","volume":"26","author":"Kakish","year":"2024","journal-title":"HPB (Oxford)"},{"key":"2026031018444651200_usaf465-B15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2026031018444651200_usaf465-B16","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clbc.2021.11.010","article-title":"Survival among breast cancer patients: comparison of the U.S. military health system with the surveillance, epidemiology and end results program","volume":"22","author":"Lin","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"2026031018444651200_usaf465-B17","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1158\/1055-9965.EPI-20-1267","article-title":"Comparison of survival among colon cancer patients in the U.S. Military Health System and patients in the Surveillance, Epidemiology, and End Results (SEER) Program","volume":"30","author":"Lin","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026031018444651200_usaf465-B18","first-page":"21","article-title":"Survival among lung cancer patients: comparison of the U.S. military health system and the surveillance, epidemiology, and end results (SEER) program by health insurance status","volume":"35","author":"Lin","year":"2024","journal-title":"Cancer Causes Control"},{"key":"2026031018444651200_usaf465-B19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026031018444651200_usaf465-B20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus Gemcitabine\/Nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg"},{"key":"2026031018444651200_usaf465-B21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamasurg.2024.2485","article-title":"Futility of up-front resection for anatomically resectable pancreatic cancer","volume":"159","author":"Crippa","year":"2024","journal-title":"JAMA Surg"},{"key":"2026031018444651200_usaf465-B22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jso.27466","article-title":"Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: timing matters","volume":"129","author":"Valdera","year":"2024","journal-title":"J Surg Oncol"},{"key":"2026031018444651200_usaf465-B23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jso.26384","article-title":"Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma","volume":"123","author":"Brown","year":"2021","journal-title":"J Surg Oncol"},{"key":"2026031018444651200_usaf465-B24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/bjs\/znac354","article-title":"Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis","volume":"110","author":"Brown","year":"2022","journal-title":"Br J Surg"},{"key":"2026031018444651200_usaf465-B25","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1245\/s10434-022-12908-z","article-title":"Impact of mediating and confounding variables on the volume-outcome association in the treatment of pancreatic cancer","volume":"30","author":"Kemp Bohan","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026031018444651200_usaf465-B26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.surg.2024.02.021","article-title":"Care fragmentation in hepatopancreatic surgery and postoperative outcomes","volume":"175","author":"Rashid","year":"2024","journal-title":"Surgery"},{"key":"2026031018444651200_usaf465-B27","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1007\/s11605-022-05478-8","article-title":"Fragmentation of care in pancreatic cancer: effects on receipt of care and survival","volume":"26","author":"Khan","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"2026031018444651200_usaf465-B28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007586","article-title":"Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma","volume":"11","author":"Katz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026031018444651200_usaf465-B29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/COC.0000000000001057","article-title":"Characteristics associated with survival in surgically nonresected pancreatic adenocarcinoma in the military health system","volume":"47","author":"Eaglehouse","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"2026031018444651200_usaf465-B30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1077558720942700","article-title":"Factors associated with the acceptance of new TRICARE and Medicare patients by health care providers","volume":"78","author":"Anand","year":"2021","journal-title":"Med Care Res Rev"},{"key":"2026031018444651200_usaf465-B31","doi-asserted-by":"crossref","first-page":"e2228783","DOI":"10.1001\/jamanetworkopen.2022.28783","article-title":"Geographic variation in appointment wait times for US military veterans","volume":"5","author":"Feyman","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026031018444651200_usaf465-B32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pan.2024.12.015","article-title":"Time between pancreatic cancer diagnosis and treatment initiation and survival in the U.S. Military Health System","volume":"25","author":"Eaglehouse","year":"2025","journal-title":"Pancreatology"},{"key":"2026031018444651200_usaf465-B33","author":"Wang","year":"2021"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/3-4\/e789\/64415486\/usaf465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/3-4\/e789\/64415486\/usaf465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:44:58Z","timestamp":1773182698000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/191\/3-4\/e789\/8266449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":33,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2025,9,20]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaf465","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,20]]}}}